New Zealand markets close in 4 hours

Portage Biotech Inc. (PRTG)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.09+0.11 (+1.58%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.98
Open7.05
Bid2.80 x 1000
Ask13.00 x 800
Day's range6.96 - 7.28
52-week range4.62 - 23.99
Volume28,681
Avg. volume45,854
Market cap94.619M
Beta (5Y monthly)131.28
PE ratio (TTM)N/A
EPS (TTM)-1.65
Earnings date24 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.25
  • GlobeNewswire

    Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

    Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its mechanism of actionWESTPORT, Conn., June 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company presented early data from its Phase 1/2

  • GlobeNewswire

    Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

    Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer vaccines developed by the NCI WESTPORT, Conn., April 25, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcomin

  • GlobeNewswire

    Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

    Late-breaking preclinical data generated by Stimunity suggests that packaging cGAMP STING activator in a virus-like particle leads to activation of tumor-specific T cellsWESTPORT, Conn., April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented in coll